# US 2004/0072272 A1 · Method for diagnosing immunologic food sensitivity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0072272 A1
- Document ID: US20040072272A1
- Status: Published application
- Kind: A1
- Application number: 10/670,100
- Filed: 2003-09-24
- Published: 2004-04-15
- Earliest claimed: 2000-03-15
- Inventors: Kenneth D. Fine
- Web page: https://patentgrep.com/patent/US20040072272A1

## CPC

- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/02: Nutritional disorders
- G01N 2800/24: Immunology or allergic disorders
- Y10S 435/971: Capture of complex after antigen-antibody reaction
- Y10S 436/811: Test for named disease, body condition or organ function
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The invention includes novel methodology for diagnosing immunologic food or drug sensitivities. The method for diagnosing food sensitivities includes using diagnoses of other related disorders, such as microscopic colitis or other chronic immunologic/autoimmune syndromes, chronic diarrhea, irritable bowel syndrome, and hepatitis C and other hepatic diseases, Crohn's disease, alcoholism, and other idiopathic neuropsychiatric and neurologic disorders, as indicators in the diagnosis of the food sensitivety. Additionally, failure to respond to or a relapse after treatment for microscopic colitis with bismuth subsalicylate is disclosed by the present invention as being a further indicator in the diagnosis of immunologic food sensitivity. Finally, the presence of certain HLA-DQ alleles, particularly HLA-DQ1,3; -DQ1,7; -DQ1,8; and -DQ1,9, HLA-DQ1,1, and at least two subtypes of the HLA-DQ1 allele identified by molecular analysis as HLA-DQB1*0501 and HLA-DQB1*0602, as indicators in diagnosing immunologic food sensitivity, particularly gluten sensitivity or celiac sprue, and in diagnosing the related disease of microscopic colitis and other autoimmune disorders is also disclosed by the invention. A method for food sensitivity panel testing (for sensitivities other than gluten sensitivity) by detecting IgA antibodies in serum is also disclosed. A method for testing stool samples for the presence of particular antibodies, which is more sensitive and less invasive than prior art testing methods, is also disclosed for diagnosing immunologic food sensitivities. These methods of diagnosis may be used alone or in combination to further enhance the accuracy of diagnosis.

## Claims

### Claim 1

A method for diagnosing an immunologic food sensitivity comprising the steps of:
collecting a fecal sample;
screening the fecal sample to detect the presence of an antibody to a particular food substance; and
diagnosing an immunologic food sensitivity based on the presence of the antibody.

### Claim 2 (depends on 1)

The method of claim 1 further comprising the step of concentrating the fecal sample to obtain a testing portion after said collecting step and wherein said testing portion is the sample in said screening step.

### Claim 3 (depends on 2)

The method of claim 2 wherein the testing portion is undiluted.

### Claim 4 (depends on 2)

The method of claim 2 further comprising the step of homogenizing the fecal sample prior to said concentrating step.

### Claim 5 (depends on 2)

The method of claim 2 wherein the testing portion is about 20 grams.

### Claim 6 (depends on 1)

The method of claim 1 wherein said screening step utilizes an enzyme-linked immunosorbant assay (ELISA) testing kit to detect the presence of an antibody to a particular food substance.

### Claim 7 (depends on 2)

The method of claim 2 wherein said screening step utilizes an enzyme-linked immunosorbant assay (ELISA) testing kit to detect the presence of an antibody to a particular food substance.

### Claim 8 (depends on 2)

The method of claim 2 wherein said concentrating step comprises the steps of:
centrifuging the fecal sample;
removing a supernatant portion from the centrifuged fecal sample; and
using the supernatant portion as the testing portion.

### Claim 9 (depends on 8)

The method of claim 8 wherein the centrifuging step is performed at a rotation speed dependant upon the viscosity of the sample.

### Claim 10 (depends on 8)

The method of claim 8 wherein tie rotation speed is between about 13,500 and 20,000 rpm.

### Claim 11 (depends on 8)

The method of claim 8 wherein the testing portion is screened undiluted and is about equal to an amount of diluted serum required by standard use of an ELISA kit.

### Claim 12 (depends on 2)

The method of claim 2 wherein said concentrating step comprises the steps of:
freeze-drying the fecal sample to a solid material; and
reconstituting the solid material with water to form a reconstituted testing portion.

### Claim 13 (depends on 12)

The method of claim 12 wherein said reconstituted testing portion is about 25% solid material and about 75% water.

### Claim 14 (depends on 2)

The method of claim 2 wherein said fecal sample contains more than about 90% water in its excreted state and wherein said concentrating step comprises the steps of:
freeze-drying the fecal sample to a solid material; and
reconstituting the solid material with water to form a reconstituted testing portion.

### Claim 15 (depends on 1)

The method of claim 1 wherein the immunologic food sensitivity is gluten sensitivity or celiac sprue.

### Claim 16 (depends on 15)

The method of claim 15 wherein the antibody is antigliadin IgA or antitissue transglutaminase IgA.

### Claim 17 (depends on 2)

The method of claim 2 wherein the immunologic food sensitivity is gluten sensitivity or celiac sprue.

### Claim 18 (depends on 17)

The method of claim 17 wherein the antibody is antigliadin IgA or antitissue transglutaminase IgA

### Claim 19 (depends on 1)

The method of claim 1 wherein the immunologic food sensitivity is yeast sensitivity.

### Claim 20 (depends on 2)

The method of claim 2 wherein the immunologic food sensitivity is yeast sensitivity.

### Claim 21 (depends on 19)

The method of claim 19 wherein said yeast is Saccharomyces cervesiae.

### Claim 22 (depends on 1)

The method of claim 1 wherein the immunologic food sensitivity is milk sensitivity.

### Claim 23 (depends on 22)

The method of claim 22 wherein the milk sensitivity is lactalbumin, casein, or bovine serum albumin sensitivity.

### Claim 24 (depends on 1)

The method of claim 1 wherein immunologic food sensitivity is egg sensitivity.

### Claim 25 (depends on 24)

The method of claim 24 wherein the egg sensitivity ovalbumin sensitivity.

### Claim 26

A method of diagnosing an immunologic food sensitivity comprising the step of detecting the presence of an HLA-DQ1,3 allele, a subtype of an HLA-DQ1,3 allele, an HLA-DQ1,1 allele, or a subtype of an HLA-DQ1 allele in a patient under diagnosis.

### Claim 27 (depends on 26)

The method of claim 26 wherein the food sensitivity is gluten sensitivity or celiac sprue.

### Claim 28 (depends on 26)

The method of claim 26 wherein said subtype of HLA-DQ1,3 is HLA-DQ1,7; HLA-DQ1,8; or HLA-DQ1,9.

### Claim 29 (depends on 26)

The method of claim 26 wherein said subtype of HLA-DQ1 is HLA-DQB1*0501 or HLA-DQB1*0602.

### Claim 30

A method of diagnosing microscopic colitis comprising the step of detecting the presence of an HLA-DQ2 allele, an HLA-DQ8 allele, an HLA-DQ1,3 allele, a subtype of an HLA-DQ1,3 allele, an HLA-DQ1,1 allele, or a subtype of an HLA-DQ1 allele in a patient under diagnosis.

### Claim 31 (depends on 30)

The method of claim 30 wherein said subtype of HLA-DQ 1,3 is HLA-DQ1,7; HLA-DQ1,8; or HLA-DQ1,9.

### Claim 32 (depends on 30)

The method of claim 30 wherein said subtype of HLA-DQ1 is HLA-DQB1*0501 or HLA-DQB1*0602.

### Claim 33

A method of diagnosing an immunologic food sensitivity comprising the steps of:
identifying a patient at risk for immunologic food sensitivity;
collecting a bodily fluid sample or tissue sample;
screening the sample to detect the presence of an antibody to a particular food substance; and
diagnosing an immunologic food sensitivity based on the presence of the antibody.

### Claim 34 (depends on 33)

The method of claim 33 wherein said identifying step comprises the step of diagnosing the patient with a disease or disorder related to an immunologic food sensitivity.

### Claim 35 (depends on 34)

The method of claim 34 wherein said related disease or disorder presents similar symptoms as said immunologic food sensitivity.

### Claim 36 (depends on 35)

The method of claim 35 wherein said symptoms are malabsorption of fluids, malabsorption of dietary nutrients, vitamin deficiency, osteoporosis, fatigue, anemia, diarrhea, weight loss, bloating, flatulence, abdominal pain, constipation, nausea, growth retardation in children, seizures, and other unexplained neurologic symptoms.

### Claim 37 (depends on 34)

The method of claim 34 wherein said related disease or disorder is irritable bowel syndrome, microscopic colitis, chronic diarrhea, chronic liver disease, gastroesophageal reflux, hepatitis C, hepatic disease, Crohn's disease, an autoimmune disease, autism, alcoholism, idiopathic neurologic syndromes, or neuropsychiatric syndromes.

### Claim 38 (depends on 34)

The method of claim 34 wherein said related disease or disorder has a genetic association with an HLA-DQ2; HLA-DQ8; HLA-DQ1,3; HLA-DQ1,7; HLA-DQ1,8; HLA-DQ1,9, HLA-DQ1,1, HLA-DQB1*0501 or HLA-DQB1*0602 allele.

### Claim 39 (depends on 33)

The method of claim 33 wherein said identifying step comprises detecting the presence of an HLA-DQ1,3 or a subtype of an HLQ-DQ1,3 allele in the patient.

### Claim 40 (depends on 39)

The method of claim 39 wherein said subtype is HLA-DQ1,7; HLA-DQ1,8; or HLA-DQ1,9.

### Claim 41 (depends on 33)

The method of claim 33 wherein said screening step utilizes an enzyme-linked immunosorbant assay (ELISA) testing kit to detect the presence of an antibody to a particular food substance.

### Claim 42 (depends on 34)

The method of claim 34 wherein said screening step utilizes an enzyme-linked immunosorbant assay (ELISA) testing kit to detect the presence of an antibody to a particular food substance

### Claim 43 (depends on 33)

The method of claim 33 wherein said sample is a fecal sample.

### Claim 44 (depends on 43)

The method of claim 43 further comprising the step of concentrating said fecal sample to obtain a testing portion prior to said screening step and wherein said testing portion is the sample in said screening step.

### Claim 45 (depends on 44)

The method of claim 44 further comprising the step of homogenizing the fecal sample prior to concentrating said sample.

### Claim 46 (depends on 44)

The method of claim 44 wherein the testing portion is screened undiluted and is about equal to an amount of diluted serum required by standard use of an ELISA kit.

### Claim 47 (depends on 33)

The method of claim 33 wherein the immunologic food sensitivity is gluten or celiac sprue.

### Claim 48 (depends on 47)

The method of claim 47 wherein the antibody is antigliadin IgA or antitissue transglutaminase IgA.

### Claim 49

A method for diagnosing an immunologic drug sensitivity comprising the steps of:
collecting a fecal sample;
screening the fecal sample to detect the presence of an antibody to a particular drug substance; and
diagnosing an immunologic drug sensitivity based on the presence of the antibody.

### Claim 50 (depends on 49)

The method of claim 49 further comprising the step of concentrating the fecal sample to obtain a testing portion prior to said screening step and wherein said testing portion is the sample in said screening step.

### Claim 51 (depends on 50)

The method of claim 50 wherein said screening step utilizes an enzyme-linked immunosorbant assay (ELISA) testing kit to detect the presence of an antibody to a particular drug substance.

### Claim 52 (depends on 50)

The method of claim 50 wherein said concentrating step comprises the steps of:
centrifuging the fecal sample;
removing a supernatant portion from the centrifuged fecal sample; and
using the supernatant portion as the testing portion.

### Claim 53 (depends on 50)

The method of claim 50 wherein the testing portion is screened undiluted and is about equal to an amount of diluted serum required by standard use of an ELISA kit.

### Claim 54 (depends on 50)

The method of claim 50 wherein said concentrating step comprises the steps of:
freeze-drying the fecal sample to a solid material; and
reconstituting the solid material with water to form a reconstituted testing portion.

### Claim 55

A method of diagnosing an immunologic food sensitivity comprising the steps of:
diagnosing a patient with microscopic colitis;
treating the patient's microscopic colitis with bismuth subsalicylate;
diagnosing an immunologic food sensitivity if the patient's microscopic colitis does not respond to the bismuth subsalicylate treatment or if the patient's microscopic colitis relapses after treatment.

### Claim 56 (depends on 55)

The method of claim 55 further comprising the following steps:
collecting a fecal sample;
screening the fecal sample to detect the presence of an antibody to a particular food substance; and
confirming diagnosis of an immunologic food sensitivity based on the presence of the antibody.

### Claim 57 (depends on 56)

The method of claim 56 further comprising the step of concentrating the fecal sample to obtain a testing portion and wherein said testing portion is the sample in said screening step.

### Claim 58 (depends on 57)

The method of claim 57 further comprising the step of homogenizing the fecal sample prior to concentrating said sample.

### Claim 59 (depends on 56)

The method of claim 56 wherein said screening step utilizes an enzyme-linked immunosorbant assay (ELISA) testing kit to detect the presence of an antibody to a particular food substance.

### Claim 60 (depends on 57)

The method of claim 57 wherein said concentrating step comprises the steps of:
centrifuging the fecal sample;
removing a supernatant portion from the centrifuged fecal sample; and
using the supernatant portion as the testing portion.

### Claim 61 (depends on 57)

The method of claim 57 wherein the testing portion is screened undiluted and is about equal to an amount of diluted serum required by standard use of an ELISA kit.

### Claim 62 (depends on 57)

The method of claim 57 wherein said concentrating step comprises the steps of:
freeze-drying the fecal sample to a solid material; and
reconstituting the solid material with water to form a reconstituted testing portion.

### Claim 63 (depends on 55)

The method of claim 55 wherein the immunologic food sensitivity is gluten sensitivity or celiac sprue.

### Claim 64 (depends on 63)

The method of claim 63 wherein the antibody is antigliadin IgA or antitissue transglutaminase IgA.
